Showdown over Sarepta's muscular dystrophy drug

In this video

Share

Showdown over Sarepta's muscular dystrophy drug

Joe Edelman, Perceptive Advisors CEO, is a Sarepta shareholder and believes the company's experimental drug in clinical trials "eteplirsen" will be approved by the FDA. The drug is proposed to treat Duchenne muscular dystrophy.
03:23
Thu, May 5 201612:31 PM EDT